Quantcast

Latest Ipilimumab Stories

2014-07-01 16:25:46

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Bristol-Myers Squibb Company - Product Pipeline Review - 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/bristol_myers_squibb_company_product_pipeline_review_2013.html Bristol-Myers Squibb Company - Product Pipeline Review - 2014 SummaryGlobal Markets Direct's, 'Bristol-Myers Squibb Company - Product Pipeline Review - 2014', provides an overview of the Bristol-Myers Squibb...

2014-06-02 08:29:32

Phase 1 Study Evaluating Talimogene Laherparepvec Plus Ipilimumab Showed Tolerability at Doses Administered THOUSAND OAKS, Calif., June 2, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th...

2014-05-31 08:21:17

Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that data from the PROCLAIM(SM) national patient registry retrospective cohort document an improvement in median overall survival (OS) in patients with metastatic melanoma who were treated with high-dose Proleukin(®) (aldesleukin) as compared to...

2014-05-27 12:32:22

SEATTLE, May 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing of the adaptive immune system, and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology. Data will also be presented demonstrating how immunosequencing can be used to elucidate the activity of immunotherapeutic combination...

2014-03-17 08:29:07

HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers. "Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective...

2014-03-15 08:21:28

DALLAS, March 15, 2014 /PRNewswire/ -- ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" research reports in its store. According to Epilepsy Therapeutics in Asia Pacific Markets to...

2014-02-20 08:31:11

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Summary GBI Research has released the pharmaceutical report "Prostate Cancer Therapeutics Market to 2019 - Rising...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related